HighMorph is presented, an interaction-guided framework that combines protein–protein interaction information with artificial intelligence for rational cyclic peptide design and provides insights for developing therapeutics targeting challenging protein interfaces.
M. Lan, Cheng-Yun Zhang, Wentong Wang et al.· Journal of Medicinal Chemist...· 0 citations
Peptide lasso-grafting strategies enable the transfer of established pharmacophores into compact protein scaffolds but often require optimization to preserve target binding and biological activity. Here, we report Random in-vitro Protein single-Loop Engineering (RiPLE), an mRNA-display strategy for the direct discovery...
Kilian Colas, T. Ko, G. Philippe et al.· bioRxiv· 0 citations
EvoBind-multimer is presented, a deep learning framework for the de novo design of molecular glues directly from protein sequences that generates small macrocyclic peptides that bridge user-defined protein pairs without requiring prior interface knowledge or existing ligands.
Andrä Brunner, Krzysztof Wierbiłowicz, Diandra Daumiller et al.· bioRxiv· 0 citations
Peptide library generation by chemical synthesis allows using a wide range of non-canonical amino acids and thus the screening of chemically and structurally highly diverse libraries. However, despite recent improvements in high-throughput synthesis such as solid-phase peptide synthesis in 384-well plates, the size of...
Anne Zarda, Xing-Wang Deng, Edward J. Will et al.· Angewandte Chemie· 0 citations
De novo design of protein binders requires a target structure. However, for flexible targets, such as intrinsically disordered proteins, this structure does not exist until the binder has stabilized the interaction. Such targets are therefore difficult for methods that separate structure generation from sequence design...
Kai Yi, Qing-Chao Chen, Dong-Qi Zhang et al.· bioRxiv· 0 citations
Irreversible covalent inhibitors have garnered significant attention in recent years. Despite encouraging progress, the vast majority contain electrophiles that target the least abundant amino acid cysteine, substantially limiting target inhibitor design for therapeutic intervention. Here, we generalize 2-ethynylbenzal...
Paul M. Levine, Patrick W. Erickson, Timothy W. Craven et al.· ACS Chemical Biology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.